Several small molecule inhibitors are being developed, but, currently, BGB324 (R248) is the only selective AXL inhibitor that is used in phase I clinical trials for patients suffering from non-small cell lung cancer or acute myeloid leukemia [19,20]. This evidence concerns the gene AXL and acute myeloid leukemia.